Hepatic safety also confirmed over six months of treatment with mealtime liver targeted insulin Company focused on Phase 3 initiation in 2020 CLEVELAND, June 10, 2019 (GLOBE NEWSWIRE) -- Diasome ...

CLEVELAND, June 04, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin to ...

While some high-yield dividend ETFs offer massive yields that entice investors, their returns can be underwhelming over time. Investors may receive a large dividend payout from these ETFs, but the ...

iShares Core High Dividend ETF comprises 75 high-quality U.S. securities that pay above-average dividend yields and pass Morningstar's Economic Moat, Uncertainty, and Distance to Default screens. Its ...

iShares Core High Dividend ETF holds 75 high-quality stocks screened by Morningstar's proprietary Wide Moat and Distance To Default rating system. Expenses are low at 0.08%, and the ETF yields 4.15%.

An investigational liver-targeted formulation of fast-acting insulin may help minimize hypoglycemia in patients with poorly controlled type 1 diabetes, new research suggests. Findings regarding ...

The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Morningstar Dividend Yield Focus Index. The Fund generally invests at ...

The iShares Core High Dividend ETF (NYSEARCA:HDV) and the Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) are two popular dividend ETFs from blue-chip sponsors. Both are cost-effective options with ...

Exchange-traded funds (ETFs) provide a convenient way for investors to get a basket of quality dividend stocks. The iShares Core High Dividend ETF is one of the most popular high-yield ETFs. There are ...

One of the best ways to safeguard your portfolio is with high-yielding assets. With markets still volatile with trade war fears, geopolitical tension, and a weaker dollar, one of the best ways to ...